Exonate plans to initiate phase 2b CLEAR-DE trial for EXN407 topical formulation for NPDR

Published on July 30, 2025
The first-in-class, twice-daily topical formulation is intended for the treatment of non-proliferative diabetic retinopathy and diabetic macular edema.
Continue reading on website
Other news

Who is faster? An optometrist or a horse?

July 30, 2025
IP optometrist, Laura Williams, and dispensing optician, Nick Black, took part in an annual race that pits runners against horses

Meta-analysis Compares Safety and Efficacy of Omidenepag to Prostaglandins

July 31, 2025
Ocular discomfort, photophobia and conjunctival hyperemia are potential side effects of omidenepag use but the drug is less likely than a prostaglandin to induce orbitopathy (pictured, OS) following chronic use. Whether transient or permanent, side effects may deter patients from using their medication. Clinicians should counsel patients about the expected onset and duration of any potential sympt